Abstract: The present disclosure relates generally to a structure-modeling approach to identify therapeutic and diagnostic targets on proteins. Means are provided to generate agents which bind and optionally antagonize a particular domain within a protein referred to as a Cleaved_Adhesin Family Domain. In an embodiment, the disclosure is directed to the control of Porphyromonas gingivalis infection or infection by related microorganisms by targeting selected domains on protease-like molecules having a hemagglutinin region. In another embodiment, the present invention enables the modulation or detection of a protein having a Cleaved_Adhesin domain homologous to those in the protease-like molecules.

Abstract: The invention relates to agents for the treatment of hepatitis C virus infection. More specifically, the invention relates to antagonists of cannabinoid type 1 receptor signalling pathway proteins and their use for the treatment of hepatitis C virus infection.

Abstract: The present invention relates to cyclic peptides, comprising alternating D- and L- amino acids and wherein the peptide possesses immunomodulatory activity. The present invention also relates to pharmaceutical compositions comprising the cyclic peptides and to methods for the treatment of disease.

Abstract: A biomedical return electrode for electrosurgery or radiofrequency (RF), a biomedical electrode pad (100), a system (300), and a method of treating tissue using a biomedical return electrode are disclosed. The biomedical return electrode comprises an electrode conductor (114) for receiving electrical energy from tissue via a return path, and a thermochromic liquid crystal (TLC) layer (116) coupled to the conductor (114). The TLC layer (116) changes color at one or more sites dependent upon the conductor temperature at each site. The TLC layer (116) changes color in a predetermined range of temperatures from about 40° C. to about 50° C. to alert an operator about the risk of a burn occurring. The biomedical electrode pad (100) comprises at least one such biomedical return electrode and a conductive body (112) to form a contact with tissue. The system (300) comprises an apparatus for delivering electrical energy to tissue and such a biomedical electrode pad (100).

Abstract: A re-use prevention mechanism (160) for an apparatus (110) having a reusable part (120) and a single-use disposable part (130) connectable to the reusable part (120) is disclosed. The re-use prevention mechanism (160) comprises a blocking portion (1603) disposed, in use, between the disposable part (130) and the reusable part (120). An actuating member (1605) is operable between the blocking portion (1603) and one of the disposable part (130) and the reusable part (120) for moving the blocking portion (1603) into a blocking position upon disconnection of the disposable part (130) from the reusable part (120). hi the blocking position, the blocking portion (1603) engages an abutment surface (1206) on one of the disposable part (130) and the reusable part (120) if a user attempts to reconnect the disposable part (130) to the reusable part (120) and thereby prevents re-connection of the disposable part (130) to the reusable part (120).

Abstract: A re-use prevention mechanism (160) for an apparatus (110) having a reusable part (120) and a single-use disposable part (130) connectable to the reusable part (120) is disclosed. The re-use prevention mechanism (160) comprises a blocking portion (1603) disposed, in use, between the disposable part (130) and the reusable part (120). An actuating member (1605) is operable between the blocking portion (1603) and one of the disposable part (130) and the reusable part (120) for moving the blocking portion (1603) into a blocking position upon disconnection of the disposable part (130) from the reusable part (120). In the blocking position, the blocking portion (1603) engages an abutment surface (1206) on one of the disposable part (130) and the reusable part (120) if a user attempts to reconnect the disposable part (130) to the reusable part (120) and thereby prevents re-connection of the disposable part (130) to the reusable part (120).

Abstract: A method (100) of determining cumulative absolute risk of breast cancer for a woman is disclosed. The method (100) assists women and doctors to make informed decisions about the additional risk of breast cancer from HRT use. The disclosed method and the implementation of the methods as software such as an application program executing within a computer system may also be used for many other diseases.

Abstract: A biomedical return electrode for electrosurgery or radiofrequency (RF), a biomedical electrode pad (100), a system (300), and a method of treating tissue using a biomedical return electrode are disclosed. The biomedical return electrode comprises an electrode conductor (114) for receiving electrical energy from tissue via a return path, and a thermochromic liquid crystal (TLC) layer (116) coupled to the conductor (114). The TLC layer (116) changes colour at one or more sites dependent upon the conductor temperature at each site. The TLC layer (116) changes colour in a predetermined range of temperatures from about 40° C. to about 50° C. to alert an operator about the risk of a burn occurring. The biomedical electrode pad (100) comprises at least one such biomedical return electrode and a conductive body (112) to form a contact with tissue. The system (300) comprises an apparatus for delivering electrical energy to tissue and such a biomedical electrode pad (100).

Abstract: The present invention relates to molecular methods of serotyping Streptococcus pneunoniae, as well as polynu-cleotides useful in such methods. These methods rely on analysing at least a portion of the nucleotide sequence between the 3? end of the cpsA gene and the 5? end of the cpsB gene, and/or analysing at least a portion of the szy and/or wzx gene(s).

Abstract: Methods for treating or preventing renal disease or inducing passive immunity against renal disease by administering polynucleotides encoding MCP-1 or both MCP-1 and RANTES are provided. Compositions containing polynucleotides encoding MCP-1 or both MCP-1 and RANTES are also provided.